• Mashup Score: 10

    Theranostics is the combination of two approaches—diagnostics and therapeutics—applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S. Food and Drug Administration (FDA) approval of lutetium 177 (177Lu) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE) and 177Lu–prostate-specific membrane antigen vector-based radionuclide therapies. The field of theranostics has imminent potential for emerging clinical applications. This article reviews critical areas of active clinical advancement in theranostics, including forthcoming clinical trials advancing FDA-approved and emerging radiopharmaceuticals, approaches to dosimetry calculations, imaging of different radionuclide therapies, expanded indications for currently used theranostic agents to treat a broader array of cancers, and emerging ideas in the field. Keywords: Molec

    Tweet Tweets with this article
    • RT @radiolobt: A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements https://t.co/iJJCgecaRv 🔵Very nice…

  • Mashup Score: 4

    Objectives To evaluate MRI diagnostic performance in detecting clinically significant prostate cancer (csPCa) in peripheral-zone PI-RADS 4 lesions, comparing those with clearly restricted diffusion (DWI-score 4), and those with equivocal diffusion pattern (DWI-score 3) and positive dynamic contrast-enhanced (DCE) MRI. Methods This observational prospective study enrolled 389 men referred to MRI…

    Tweet Tweets with this article
    • https://t.co/OZMygpHHV7 Categorizing PI-RADS 3 lesions in PI-RADS 3 and “3up” (enhancement) dilutes PI-RADS 4. Thus, only men with elevated PSAD or other risk factors should undergo biopsy. Further validation is needed. The EAU-guideline-table may help what to do in PI-RADS 3. https://t.co/uNB4RL1cBo

  • Mashup Score: 0

    Kanker.nl is de plek voor betrouwbare informatie en ervaringen van anderen. Stel je vraag over kanker, ontmoet lotgenoten of schrijf je eigen blog. We zijn er voor je.

    Tweet Tweets with this article
    • RT @BigChallenges: @JelleBarentsz geeft antwoord op vragen op https://t.co/qvogzOvYZx https://t.co/BWOwT5JXot